venetoclax + atezolizumab + carboplatin + etoposide

This is a combination regimen consisting of four agents: **venetoclax** (a selective small molecule inhibitor of B-cell lymphoma 2), **atezolizumab** (a humanized monoclonal antibody targeting programmed death-ligand 1, PD-L1), **carboplatin** (a platinum-based cytotoxic chemotherapeutic agent), and **etoposide** (a topoisomerase II inhibitor). - **Venetoclax** induces apoptosis in cancer cells by inhibiting the anti-apoptotic protein BCL-2, primarily used in hematologic malignancies. - **Atezolizumab** blocks PD-L1, preventing inhibition of T-cell mediated anti-tumor activity, classifying as an immune checkpoint inhibitor. - **Carboplatin** intercalates with and damages DNA, leading to apoptosis in rapidly dividing tumor cells. - **Etoposide** impairs cell division by inhibiting the enzyme topoisomerase II, promoting DNA strand breaks and cancer cell death. This combination has potential use in aggressive hematologic malignancies, including Richter transformation and variants of lymphoma and possibly small-cell lung cancer, though the exact combination with all four components is not established as a standard regimen in any disease. Individual drugs within this set are approved and commonly used in various cancers; this particular quartet would be used in research settings exploring synergistic antitumor efficacy[2][3][4][8].

Brand names

Venclexta + Tecentriq + Paraplatin + VePesid

Other names

venetoclax + atezolizumab + carboplatin + etoposide